Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

Swine Vaccines Market Size & Growth Forecast 2026–2035, By Segments (Product, Route of Administration, Disease Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 11228| Published Date: Mar-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

Swine Vaccines Market size was worth USD 1.82 Billion in 2025 and is poised to grow at a 5.6% CAGR between 2026 and 2035, reaching USD 3.14 Billion by 2035. The industry revenue for 2026 is assessed at USD 1.9 billion.

Base Year Value (2025)
USD 1.82 Billion
CAGR (2026-2035)
5.6%
Forecast Year Value (2035)
USD 3.14 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

Swine Vaccines Market Intelligence Snapshot

Regional Market Dynamics

  • North America held a 40.77% market share in 2025, supported by established commercial swine production, preventive veterinary practices, and routine vaccine use across large-scale farming operations.
  • Asia Pacific is projected to grow at a 6.33% CAGR as expanding pork production systems increasingly adopt preventive vaccination to improve herd health, reduce disease losses, and enhance farm productivity.

Segment Momentum

  • Inactivated (Killed) vaccines accounted for 54.63% of the market in 2025 due to their established role in routine herd health programs, dependable handling, and broad acceptance across commercial swine production systems.
  • Oral administration is expanding fastest because it enables more practical herd-level vaccination, reduces handling intensity, and supports efficient large-scale vaccine deployment where labor efficiency and ease of administration are priorities.

Market Expansion Drivers

  • Rising prevalence of ASF and PRRS outbreaks increasing swine vaccination program adoption.
  • Growing global pork consumption driving herd health management and preventive vaccination demand.
  • Advancements in needle-free and multivalent vaccine technologies improving farm operational efficiency.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Major companies in the swine vaccines market include Zoetis Inc. (United States), Merck & Co., Inc. (United States), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (United States), Ceva Santé Animale (France), HIPRA, S.A. (Spain), Virbac S.A. (France), Phibro Animal Health Corporation (United States), Biogénesis Bagó S.A. (Argentina), Indian Immunologicals Ltd. (India).

Regional and Segment Outlook

North America
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Rising prevalence of ASF and PRRS outbreaks increasing swine vaccination program adoption

Recurring ASF and PRRS outbreaks are reshaping purchasing behavior in the swine vaccines market by pushing producers, integrators, and veterinary networks toward more structured preventive health programs. Disease events raise the cost of herd instability through mortality, reproductive losses, movement restrictions, and disrupted supply contracts, which makes vaccination planning a routine operating decision rather than a discretionary expense. This transition is increasing demand for the swine vaccines market through broader protocol adoption, tighter coordination with veterinarians, and more consistent procurement of vaccines designed to reduce outbreak exposure and limit production volatility.

Growing global pork consumption driving herd health management and preventive vaccination demand

As pork consumption expands, producers are under pressure to maintain larger, more productive herds with predictable output, which increases the commercial importance of disease prevention. In the swine vaccines market, this translates into stronger adoption of routine vaccination as farms seek to protect feed conversion, growth performance, and breeding efficiency while minimizing losses that can interrupt processor supply and downstream distribution. The result is a closer link between production planning and preventive healthcare spending, encouraging market growth as vaccination becomes embedded in modern herd health management.

Advancements in needle-free and multivalent vaccine technologies improving farm operational efficiency

Technology improvements are influencing market adoption by making vaccination easier to deploy at scale under commercial farm conditions. In the swine vaccines market, needle-free systems help reduce administration time, needle-related injury risks, and cross-contamination concerns, while multivalent products lower handling frequency by covering multiple pathogens in fewer interventions. These practical efficiencies matter in large herds where labor availability, animal stress, and scheduling precision directly affect compliance with vaccination protocols, supporting market development for products that improve both health outcomes and day-to-day farm execution.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Rising prevalence of ASF and PRRS outbreaks increasing swine vaccination program adoption 1.90% High Asia Pacific, Europe High Near Term
Growing global pork consumption driving herd health management and preventive vaccination demand 1.60% Moderate Asia Pacific, North America High Mid Term
Advancements in needle-free and multivalent vaccine technologies improving farm operational efficiency 1.30% Moderate Europe, North America Medium Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
40.77% Market Share in 2025
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional position in 2025, accounting for a 40.77% share of the swine vaccines market. This leadership is sustained by the region’s established commercial swine production systems, where disease prevention is closely tied to productivity, herd health, and supply continuity. Vaccination demand is strengthened by structured animal health management practices, stronger adoption of preventive veterinary protocols, and the routine integration of vaccines into large-scale farm operations, which keeps purchasing patterns comparatively stable and supports continued market dominance.

Asia Pacific is projected to expand at a 6.33% CAGR over the forecast period in the swine vaccines market, driven by the increasing need to protect large and growing swine populations from production-limiting diseases. Growth is being impelled by the practical shift toward more organized disease control across expanding pork production systems, where producers are placing greater emphasis on preventive health measures to reduce losses and improve farm output. As vaccination becomes more embedded in day-to-day herd management, regional uptake is accelerating across commercial operations.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Precision Disease Control

Germany focuses on preventive swine health management through targeted vaccination and strong veterinary monitoring. German livestock producers increasingly adopt vaccines alongside biosecurity measures to maintain herd productivity and support efficient disease control practices.

France 🇫🇷

Commercial Herd Resilience

France supports swine vaccine adoption through integrated herd health management and preventive veterinary practices. French producers increasingly combine vaccination with surveillance and farm management improvements to maintain stable livestock production and animal welfare standards.

Italy 🇮🇹

Farm Health Management

Italy is expanding the use of swine vaccines as part of practical disease prevention strategies across commercial pig farms. Veterinary services in Italy are promoting vaccination schedules and biosecurity measures that strengthen herd health and improve production continuity.

Japan 🇯🇵

Biosecure Livestock Protection

Japan emphasizes preventive vaccination supported by strict animal health standards and intensive disease monitoring. Swine producers in Japan continue adopting high-quality vaccines that fit integrated herd management strategies while minimizing disease-related production risks.

South Korea 🇰🇷

Veterinary Prevention Strategy

South Korea continues strengthening swine disease prevention through coordinated vaccination programs and enhanced livestock health management. Vaccine adoption in South Korea is supported by continuous monitoring, veterinary collaboration, and improved farm biosecurity practices.

United States 🇺🇸

Herd Health Programs

The U.S. prioritizes comprehensive swine vaccination strategies to improve herd health and reduce production losses from infectious diseases. Vaccine developers are supporting producers with advanced immunization programs, disease surveillance, and updated vaccine technologies for commercial operations.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

Swine Vaccines Market Share (%), Product, 2025

Inactivated (Killed)
Modified/Attenuated Live
Others

Go beyond the chart, access full insights & data tables

Request Free Sample Report
Product Segment Analysis: Inactivated (Killed) (Largest Segment) vs Modified/Attenuated Live (Fastest-Growing Segment)

Within the swine vaccines market, Inactivated (Killed) held the dominant position in 2025 with a 54.63% share. This segment’s leadership is underpinned by its established use in routine herd health programs, where producers and veterinarians often prioritize dependable handling, broad field familiarity, and fit with structured vaccination schedules. Its continued dominance in the swine vaccines market reflects the practical preference for products that are already well integrated into commercial swine production systems and widely accepted across large-scale disease prevention practices.

Modified/Attenuated Live is the fastest-growing product segment in the swine vaccines market as producers increasingly look for vaccine options that align with evolving disease pressure and more responsive immune protection strategies. Its growth momentum is underpinned by rising interest in formulations that can better match current herd management needs, especially where faster or stronger biological response is valued relative to conventional alternatives. Compared with other product types, this segment is experiencing stronger uptake because it fits the market’s shift toward more adaptive disease-control approaches in intensive swine production environments.

Route of Administration Segment Analysis: Injectables (Largest Segment) vs Oral (Fastest-Growing Segment)

Injectables accounted for the largest position in the swine vaccines market in 2025, representing a 72.76% share. Their leadership is closely tied to established administration protocols across commercial farms, where controlled dosing and consistent delivery remain central to herd vaccination programs. The segment maintains its lead in the swine vaccines market because injectable vaccines are deeply embedded in veterinary practice and farm operations, making them the default route in many organized immunization workflows.

Oral is emerging as the fastest-growing route of administration in the swine vaccines market due to the operational advantages it offers in herd-level delivery. Growth is being encouraged by the need for more practical vaccination approaches that reduce handling intensity and better suit large animal populations, especially in settings where labor efficiency and ease of administration matter. Relative to injectables and other conventional methods, oral delivery is gaining momentum because it better supports scalable vaccine deployment under modern swine production conditions.

Segment Sub-Segment Largest Segment Fastest Growing
Product Inactivated (Killed), Modified/Attenuated Live, Others Inactivated (Killed) Modified/Attenuated Live
Route of Administration Injectables, Intranasal, Oral Injectables Oral
Disease Type Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Others PRRS Foot & Mouth Disease
Competitive Landscape

Competitive Landscape and Market Positioning

Top players in the swine vaccines market:

1. Zoetis Inc. (United States)

2. Merck & Co. Inc. (United States)

3. Boehringer Ingelheim International GmbH (Germany)

4. Elanco Animal Health Incorporated (United States)

5. Ceva Santé Animale (France)

6. HIPRA S.A. (Spain)

7. Virbac S.A. (France)

8. Phibro Animal Health Corporation (United States)

9. Biogénesis Bagó S.A. (Argentina)

10. Indian Immunologicals Ltd. (India)

The swine vaccines market is witnessing heightened activity as producers focus on improving disease prevention and livestock productivity. Companies are expanding vaccine portfolios targeting emerging viral infections and region-specific disease outbreaks to strengthen their market reach. Increased collaboration with veterinary research institutions and rising investments in advanced vaccine delivery technologies are further supporting innovation and enhancing the effectiveness of immunization programs across commercial swine farming operations.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Boehringer Ingelheim Sep-25 Boehringer Ingelheim launched INGELVAC CIRCOFLEX AD in the U.S., the first single-dose swine vaccine combining PCV2a and PCV2d antigens. Designed for rapid onset of immunity and long-term protection, the vaccine addresses the rising prevalence of PCV2d strains, providing producers with an efficient tool to improve herd health and operational profitability.
European Medicines Agency Jun-25 The EMA issued a positive opinion for Biobhyo, a novel vaccine developed to prevent swine dysentery caused by Brachyspira hyodysenteriae. This regulatory milestone represents a significant advancement in controlling a major enteric disease, offering producers a targeted preventive solution to reduce reliance on antibiotics and enhance overall swine herd health.
Virbac Apr-25 Virbac launched a 2-in-1 swine vaccine in France targeting leptospirosis and porcine parvovirus in gilts and sows. By combining protection against two reproductive diseases into a single dose, the vaccine streamlines vaccination protocols, enhances immunization efficiency, and aligns with the company’s strategic focus on delivering integrated preventive health solutions to European producers.
Merck & Co., Inc. Sep-24 Merck Animal Health received marketing authorization from the EMA for PORCILIS PCV M Hyo ID, an intradermal vaccine for swine. This regulatory approval expands the company's portfolio of advanced immunization tools, providing a needle-free delivery option that enhances piglet welfare and simplifies respiratory disease management in intensive swine production systems.
Ceva Santé Animale Oct-24 Ceva Santé Animale received European marketing authorization for Cirbloc M Hyo, a combination vaccine protecting against Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae. The single-dose formulation provides extended coverage through the fattening period, reinforcing Ceva’s competitive position and commitment to simplifying respiratory health management for European swine producers.
Merck & Co., Inc. Jun-23 Merck Animal Health launched Circumvent CML, a first-of-its-kind 3-in-1 swine vaccine designed to protect against PCV-2a, PCV-2d, Mycoplasma hyopneumoniae, and Lawsonia intracellularis. By integrating multiple antigens into a single 2cc dose, the product significantly reduces labor requirements, handling stress, and the risk of application errors in swine production environments.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

Swine Vaccines Market — Custom Segments

Segment Sub-Segment
No segment data available.

Swine Vaccines Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

What is the market size of swine vaccines?

In 2026 the market for swine vaccines is valued at USD 1.9 billion.

What is the anticipated CAGR of the swine vaccines industry?

Swine Vaccines Market size is anticipated to rise from USD 1.82 billion in 2025 to USD 3.14 billion by 2035 reflecting a CAGR surpassing 5.6% over the forecast horizon of 2026-2035.

How are recurring ASF and PRRS outbreaks influencing vaccination procurement strategies in the swine vaccines market?

Frequent ASF and PRRS outbreaks are pushing producers toward structured, preventive vaccination programs as part of routine herd management. This is increasing consistent procurement, tighter veterinary coordination, and a stronger focus on reducing production volatility and disease-related losses.

How are advancements in vaccine delivery technologies affecting operational efficiency in commercial swine farming?

Needle-free and multivalent vaccine innovations are reducing administration time, animal stress, and handling frequency. These efficiencies improve compliance in large-scale farms and support broader adoption of vaccination protocols as operational demands and labor constraints increase.

Why do Inactivated (Killed) vaccines hold the largest share of the swine vaccines market?

Inactivated (Killed) vaccines accounted for 54.63% of the market in 2025 due to their established role in routine herd health programs, dependable handling, and broad acceptance across commercial swine production systems.

Why is Oral administration the fastest-growing route in the swine vaccines market?

Oral administration is expanding fastest because it enables more practical herd-level vaccination, reduces handling intensity, and supports efficient large-scale vaccine deployment where labor efficiency and ease of administration are priorities.

What factors make North America the leading swine vaccines market?

North America held a 40.77% market share in 2025, supported by established commercial swine production, preventive veterinary practices, and routine vaccine use across large-scale farming operations.

Why is demand for swine vaccines increasing in Asia Pacific?

Asia Pacific is projected to grow at a 6.33% CAGR as expanding pork production systems increasingly adopt preventive vaccination to improve herd health, reduce disease losses, and enhance farm productivity.

Which organizations are considered leaders in the swine vaccines landscape?

Major companies in the swine vaccines market include Zoetis Inc. (United States), Merck & Co., Inc. (United States), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (United States), Ceva Santé Animale (France), HIPRA, S.A. (Spain), Virbac S.A. (France), Phibro Animal Health Corporation (United States), Biogénesis Bagó S.A. (Argentina), Indian Immunologicals Ltd. (India).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →